Related Experiment Video
Updated: Mar 16, 2026
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
New hope for chronic myelogenous leukemia patients: dasatinib offers better efficacy with shorter treatment
Kazuhito Naka1, Tatsuo Ichinohe1
11 Department of Stem Cell Biology, 2 Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Abstract:
Although the discovery of tyrosine kinase inhibitors (TKIs) has dramatically improved the prognoses of chronic myelogenous leukemia (CML) patients, a cure has remained elusive. Unanswered questions include how long must a patient continue on TKI therapy, and how does a patient know when he/she can safely stop or finish this therapy? Imagawa et al. have carefully addressed these questions of safety and efficacy using a stop study of the second-generation TKI dasatinib. The results of a multicenter phase II trial termed the "dasatinib discontinuation" (DADI) trial indicated that 48% (30/63) of CML patients who had maintained a deep molecular response (DMR) to second-line or subsequent dasatinib therapy for at least for 1 year did not show any signs of disease relapse. Thus, even after it is stopped, dasatinib treatment may decrease the chance of disease relapse and provide a curative benefit to CML patients. This work by Imagawa et al. strongly supports the clinical utility of the second-generation TKI dasatinib for CML treatment.
Insights
Tyrosine kinase inhibitor (TKI) therapy for chronic myelogenous leukemia (CML) may offer a cure. A study found that 48% of CML patients stopping dasatinib after a deep molecular response did not relapse, suggesting a curative benefit.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Tyrosine kinase inhibitors (TKIs) have significantly improved chronic myelogenous leukemia (CML) outcomes, but a cure remains elusive.
- Key questions persist regarding the optimal duration of TKI therapy and criteria for safely discontinuing treatment.
- The development of second-generation TKIs like dasatinib offers new therapeutic avenues.
Discussion:
- The multicenter phase II DADI trial investigated the safety and efficacy of discontinuing dasatinib in CML patients.
- Patients who maintained a deep molecular response (DMR) for at least one year on dasatinib were assessed after treatment cessation.
- The study evaluated relapse rates and the potential for dasatinib to offer a curative benefit.
Key Insights:
- Discontinuation of dasatinib in 48% (30/63) of CML patients with DMR did not result in disease relapse.
- Sustained deep molecular response to dasatinib may allow for treatment cessation without compromising long-term outcomes.
- These findings suggest that dasatinib treatment could contribute to a potential cure for CML.
Outlook:
- Further research is needed to refine criteria for safe TKI discontinuation in CML.
- The DADI trial results support the clinical utility of dasatinib in achieving treatment-free remission.
- Investigating biomarkers predictive of sustained response after dasatinib cessation is crucial for future CML management.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:34Inhibition of Cdk Activity
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...